These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Bisphosphonate therapy. Licata AA Am J Med Sci; 1997 Jan; 313(1):17-22. PubMed ID: 9001162 [TBL] [Abstract][Full Text] [Related]
4. Role of alendronate and risedronate in preventing and treating osteoporosis. Peters ML; Leonard M; Licata AA Cleve Clin J Med; 2001 Nov; 68(11):945-51. PubMed ID: 11718433 [TBL] [Abstract][Full Text] [Related]
5. Consensus statement on the modern therapy of Paget's disease of bone from a Western Osteoporosis Alliance symposium. Biannual Foothills Meeting on Osteoporosis, Calgary, Alberta, Canada, September 9-10, 2000. Drake WM; Kendler DL; Brown JP Clin Ther; 2001 Apr; 23(4):620-6. PubMed ID: 11354395 [TBL] [Abstract][Full Text] [Related]
6. Treatment of osteoporosis with bisphosphonates. Watts NB Rheum Dis Clin North Am; 2001 Feb; 27(1):197-214. PubMed ID: 11285996 [TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates: preclinical aspects and use in osteoporosis. Fleisch HA Ann Med; 1997 Feb; 29(1):55-62. PubMed ID: 9073324 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis. Iwamoto J; Takeda T; Sato Y Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313 [TBL] [Abstract][Full Text] [Related]
9. Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate. Iwamoto J; Takeda T; Sato Y Expert Opin Pharmacother; 2007 Nov; 8(16):2743-56. PubMed ID: 17956196 [TBL] [Abstract][Full Text] [Related]
10. Gastroenterologists and choosing the right bisphosphonate. Leder BZ; Kronenberg HM Gastroenterology; 2000 Sep; 119(3):866-9. PubMed ID: 10982780 [No Abstract] [Full Text] [Related]
11. Use of highly potent bisphosphonates in the treatment of osteoporosis. McClung M Curr Osteoporos Rep; 2003 Dec; 1(3):116-22. PubMed ID: 16036074 [TBL] [Abstract][Full Text] [Related]
12. [Alternatives to hormonal treatment for the prevention of postmenopausal osteoporosis: the bisphosphonates]. Trémollières F Gynecol Obstet Fertil; 2001 Nov; 29(11):846-52. PubMed ID: 11770280 [No Abstract] [Full Text] [Related]
13. Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis. Chapurlat RD Treat Endocrinol; 2005; 4(2):115-25. PubMed ID: 15783248 [TBL] [Abstract][Full Text] [Related]
14. Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA. Eisman JA; Cortet B; Boolell M; Ionescu-Ittu R; Vekeman F; Heroux J; Thomasius F Osteoporos Int; 2023 May; 34(5):977-991. PubMed ID: 36872338 [TBL] [Abstract][Full Text] [Related]
15. [Bisphosphonates in the prevention of vertebral and non-vertebral fractures in postmenopausal women with osteoporosis]. Curković B Reumatizam; 2003; 50(2):49-50. PubMed ID: 15098377 [TBL] [Abstract][Full Text] [Related]
16. Optimizing administration of bisphosphonates in women with postmenopausal osteoporosis. Rackoff PJ; Sebba A Treat Endocrinol; 2005; 4(4):245-51. PubMed ID: 16053341 [TBL] [Abstract][Full Text] [Related]